| Field | Specification |
|---|---|
| Mfr No | |
| Product Format | Frozen |
| Product Type | |
| Shipping | |
| Storage |
Overview
Human Primary Pancreatic Islets can be split into different culture vessels (i.e. multi-well plates) for experimental needs, but they will not proliferate in vitro. The product is supplied as frozen cells.
Key elements and design rationale
- Biological source: Human (H. sapiens)
- Tissue origin: Pancreas
- Growth properties: Suspension, round
- Format: Frozen
- Donor history: Normal tissue
- Biosafety level: II
- Culture context: Refer to detailed instructions outlined below for islet handling.
Primary cells provide a biologically relevant starting point for in vitro studies because they retain tissue-linked morphology, growth behavior, and donor-associated characteristics that are often reduced in immortalized systems.
Research relevance and current trends
- Primary-cell models continue to be used when donor context, tissue specificity, and physiologic responsiveness are important.
- Researchers often combine primary cells with co-culture, matrix, or conditioned-media approaches to better reflect native microenvironments.
- Phenotypic characterization and careful tracking of culture conditions remain important for reproducible interpretation.
Common research applications
- Use in tissue-relevant in vitro assays where morphology and donor context matter.
- Measure phenotype, marker expression, or response to defined perturbations over time.
- Incorporate into co-culture or screening workflows requiring primary-cell context.
Product-specific data supplied for this listing
- Growth Conditions: Refer to detailed instructions outlined below for islet handling. The media supplied during shipment is not sufficient for islet maintenance. TM0199 (ready-to-use) is recommended for islet maintenance. Note: Human Primary Pancreatic Islets can be split into different culture vessels (i.e. multi-well plates) for experimental needs, but they will not proliferate in vitro.
- Warranty: abm warrants that cell lines shall be viable upon initiation of culture for a period of thirty (30) days after shipment and that they shall meet the specifications on the applicable abm Material Product Information sheet, certificate of analysis, and/or catalog description. Such thirty (30) day period is referred to herein as the "Warranty Period”.
- Disclaimer: 1. Sale of this item is subjected to the completion of a Material Transfer Agreement (MTA) by the purchasing individual/institution for each order. If you have any questions regarding this, please contact us at orders@biohippo.com.
Notes for experimental interpretation
- Primary cells can show donor-dependent and passage-dependent variation, so morphology, growth rate, and marker expression should be interpreted in the context of the specific lot and culture history.
- Attachment matrix, medium formulation, and gas conditions can materially influence phenotype maintenance and experimental readouts; use the recommended culture system where possible.
- Cryopreserved recovery conditions matter for viability and downstream behavior. We recommend using serum-free CryoGuard™ Freezing Media (TM078).
- Aspirate the culture media, and add 2-3ml of pre-warmed 0.25% Trypsin-EDTA to the culture vessel.
- Observe the cells under a microscope to confirm detachment (typically within 2-10 minutes). Cells that are difficult to detach can be put in 37°C, for several minutes to facilitate detachment.
- Neutralize Trypsin-EDTA by adding an equal volume of the complete growth media into the culture vessel.
- Transfer the culture suspension into a sterile centrifuge tube, and centrifuge at 125xg for 5 minutes. The actual centrifuge duration and speed may vary depending on the cell type.
- Aspirate the supernatant, and re-suspend the pellet with pre-warmed fresh complete growth media. Add appropriate aliquots of the cell suspension to new culture vessels, as desired.
- Incubate the cells at the recommended conditions.
Cell line sourcing and selection (species, tissue, and disease model matching) · Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA) · Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs) · Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles) · Inducible expression systems (Tet-On/Off and regulatable constructs) · Drug resistance marker selection (puromycin, G418, hygromycin, and others) · Custom growth and media optimisation for specific assay requirements · Scale-up production for high-throughput screening campaigns · Authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Talk to a Scientist or contact support@biohippo.com.
